Attached files
| file | filename |
|---|---|
| EX-99.1 - PRESS RELEASE, DATED APRIL 28, 2011 - ANGIOTECH PHARMACEUTICALS INC | exhibit99-1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 28, 2011
Angiotech Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
| British Columbia | 000-30334 | 98-0226269 |
| (State or other jurisdiction of incorporation) | (Commission File Number) | (IRS. Employer Identification No.) |
1618 Station Street Vancouver, BC, Canada V6A 1B6
(Address of principal executive offices and zip code)
Registrant’s telephone number, including area code: (604) 221-7676
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| [ ] | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| [ ] | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| [ ] | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| [ ] | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| Item 8.01. | Other Events. |
On April 28, 2011, Angiotech Pharmaceuticals, Inc. (the “Company”) issued a press release announcing the extension of the expiration date of its senior floating rate note exchange offer and the delivery of a supplement to the offering memorandum. A copy of the Company’s press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
| Item 9.01. | Financial Statements and Exhibits. |
(d) Exhibits. The following exhibits are filed herewith:
| Exhibit Number |
Description |
| 99.1 | Press Release, dated April 28, 2011. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Angiotech Pharmaceuticals, Inc. | |||||
| (Registrant) | |||||
| Dated: | April 29, 2011 | By: | /s/ Jay Dent | ||
| Name: | Jay Dent | ||||
| Title: | Senior Vice President, Finance | ||||